Huang Yuan-peng, Wen Yan-hui, Wu Geng-hui, Hong Zhen-feng, Xu Shang-wen, Peng A-xiang
Department of Traditional Chinese Medicine, Zhongshan Hospital, Xiamen University, Xiamen, Fujian Province, 361004, China,
Chin J Integr Med. 2014 Dec;20(12):949-54. doi: 10.1007/s11655-014-2021-1. Epub 2014 Nov 27.
To observe the effectiveness and safety of Kangquan Recipe (康泉方, KQR) for benign prostatic hyperplasia (BPH) patients.
One hundred and six BPH patients were randomly assigned to the treatment group (53 cases) and the control group (53 cases) according to a random number table. The treatment group was given KQR orally; the control group was given cernilton orally. After 24-week treatment, the clinical effect and safety were evaluated using the International Prostatic Symptom Score (I-PSS), quality of life (QOL), maximum flow rate (Qmax), average flow rate (Qave), residual urine volume (RUV), total prostatic volume (TPV), etc.
After treatment, the score of I-PSS was decreased from 16.9±5.6 to 12.5±4.6 in the treatment group, significantly lower compared with the control group; the levels of Qmax and Qave were from 10.9±3.5 to 15.6±4.5 and 5.4±2.1 to 7.3±2.5 (mL/s) in the treatment group, significantly higher compared with the control group; the levels of RUV and TPV were from 70.8±28.2 to 35.2±21.8 and 37.2±16.9 to 30.1±10.8 (mL) in the treatment group, significantly lower compared with the control group (all P<0.05). The incidence rate of adverse reaction was similar between the two groups (P>0.05).
KQR is effective and safe for the treatment of BPH.
观察康泉方（KQR）治疗良性前列腺增生症（BPH）患者的有效性和安全性。
将106例BPH患者按随机数字表法随机分为治疗组（53例）和对照组（53例）。治疗组口服康泉方；对照组口服舍尼通。治疗24周后，采用国际前列腺症状评分（I-PSS）、生活质量（QOL）、最大尿流率（Qmax）、平均尿流率（Qave）、残余尿量（RUV）、前列腺总体积（TPV）等评估临床疗效和安全性。
治疗后，治疗组I-PSS评分由16.9±5.6降至12.5±4.6，显著低于对照组；治疗组Qmax和Qave水平分别由10.9±3.5升至15.6±4.5、5.4±2.1升至7.3±2.5（mL/s），显著高于对照组；治疗组RUV和TPV水平分别由70.8±28.2降至35.2±21.8、37.2±16.9降至30.1±10.8（mL），显著低于对照组（均P<0.05）。两组不良反应发生率相似（P>0.05）。
康泉方治疗BPH有效且安全。
